Kyntra Bio Inc (KYNB) Stock Price, Quote & News

Company Profile

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 978 1200

Fax: 415 978 1902

Website: www.kyntrabio.com

Address:

350 Bay Street, Suite 100 #6009, San Francisco, United States

ARKADIY_PAROVOZOV Jul. 15 at 6:56 AM

$KYNB New notes in Biology (MDPI) related to biological research (possibly HIF pathway). Supportive scientific context for Roxadustat mechanism. https://www.mdpi.com/2079-7737/15/14/1118/notes

0 · Reply

ARKADIY_PAROVOZOV Jul. 15 at 6:55 AM

$KYNB New article in Cell Proliferation discusses cell proliferation mechanisms (possibly related to HIF). Supportive preclinical data. https://onlinelibrary.wiley.com/doi/10.1111/cpr.70230

0 · Reply

ARKADIY_PAROVOZOV Jul. 15 at 6:55 AM

$KYNB Selleckchem overview of renal anemia in CKD and treatment options including HIF-PHI. Educational resource. https://www.selleckchem.com/moa/Renal-Anemia-in-Chronic-Kidney-Disease-S1007.html

0 · Reply

ARKADIY_PAROVOZOV Jul. 15 at 6:54 AM

$KYNB New PubMed article related to Roxadustat or HIF-PHI. Supportive scientific publication. https://pubmed.ncbi.nlm.nih.gov/42417154/

0 · Reply

ARKADIY_PAROVOZOV Jul. 14 at 7:04 AM

$KYNB Vanderbilt-Ingram Cancer Center flowchart for advanced prostate cancer trials. Helpful for tracking FG-3246 development. https://vicc.org/clinical-trials/flowcharts/Genitourinary%2BCancer/Prostate%2B-%2BAdvanced

0 · Reply

ARKADIY_PAROVOZOV Jul. 14 at 7:04 AM

$KYNB UCSF clinical trials page for prostate cancer. May include FG-3246 studies. https://clinicaltrials.ucsf.edu/prostate-cancer

0 · Reply

ARKADIY_PAROVOZOV Jul. 14 at 7:03 AM

$KYNB Recent company changes tracked on Topograph. Useful for monitoring Kyntra Bio updates. https://topograph.info/changes

0 · Reply

MaxMiamiFl Jul. 14 at 1:31 AM

$KYNB 2nd half of 2026..could be starting 2027.😡😡

0 · Reply

sarah92 Jul. 12 at 6:29 PM

$KYNB Market cap is around $30M, so successful clinical progress could create outsized percentage gains..

1 · Reply

ARKADIY_PAROVOZOV Jul. 9 at 4:35 PM

$KYNB Article in The BMJ (8 July 2026) by experts from Mayo Clinic and MD Anderson highlights the urgent need for new therapies in metastatic castration-resistant prostate cancer (mCRPC). The review underscores the high value of CD46-targeted approaches like Kyntra Bio’s FG-3246. https://www.bmj.com/content/394/bmj-2025-085211

1 · Reply

Kyntra Bio initiated with an Outperform at Oppenheimer

Jun 12, 2026, 11:00 AM EDT - 4 weeks ago

Kyntra Bio Transcript: AGM 2026

2026-06-11T20:20:00.000Z - 4 weeks ago

Kyntra Bio to present additional MATTERHORN trial data at EHA

Jun 11, 2026, 4:05 PM EDT - 4 weeks ago

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes

2026-06-09T11:16:47.000Z - 5 weeks ago

Kyntra Bio initiated with a Buy at Rodman & Renshaw

May 11, 2026, 5:00 PM EDT - 2 months ago

Kyntra Bio Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

Kyntra Bio Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

Kyntra Bio Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

Kyntra Bio Quarterly report: Q1 2026

May 11, 2026, 4:05 PM EDT - 2 months ago

Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

May 4, 2026, 4:05 PM EDT - 2 months ago

Kyntra Bio to Report First Quarter 2026 Financial Results

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Kyntra Bio Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Kyntra Bio Proxy statement: Proxy filing

Apr 13, 2026, 1:30 PM EDT - 3 months ago

Kyntra Bio Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 4:05 PM EDT - 3 months ago

Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference

Mar 16, 2026, 5:00 PM EDT - 4 months ago

Kyntra Bio Earnings Call Transcript: Q4 2025

Mar 16, 2026, 5:00 PM EDT - 4 months ago

Kyntra Bio Annual report: Q4 2025

Mar 16, 2026, 5:00 PM EDT - 4 months ago

Kyntra Bio Earnings release: Q4 2025

Mar 16, 2026, 5:00 PM EDT - 4 months ago

Kyntra Bio Slides: Q4 2025

Mar 16, 2026, 4:02 PM EDT - 4 months ago

Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 11, 2026, 2:20 PM EDT - 4 months ago

Kyntra Bio Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 7:00 AM EDT - 4 months ago

Kyntra Bio Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 4 months ago

Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 2:40 PM EST - 4 months ago

Kyntra Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-02-23T22:16:08.000Z - 5 months ago

Kyntra Bio announces positive data from Phase 1b/2 study of FG-3246

Feb 23, 2026, 5:10 PM EST - 5 months ago

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

Feb 17, 2026, 4:05 PM EST - 5 months ago

Kyntra Bio to Participate in Upcoming Investor Conferences

Jan 7, 2026, 7:30 AM EST - 6 months ago

FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

Nov 10, 2025, 5:00 PM EST - 8 months ago

Kyntra Bio Earnings Call Transcript: Q3 2025

Nov 10, 2025, 5:00 PM EST - 8 months ago

Kyntra Bio Quarterly report: Q3 2025

Nov 10, 2025, 5:00 PM EST - 8 months ago

Kyntra Bio Earnings release: Q3 2025

Nov 10, 2025, 5:00 PM EST - 8 months ago

Kyntra Bio Slides: Q3 2025

Nov 3, 2025, 4:02 PM EST - 9 months ago

FibroGen to Report Third Quarter 2025 Financial Results

Sep 24, 2025, 7:00 AM EDT - 10 months ago

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

Sep 9, 2025, 12:00 PM EDT - 11 months ago

Kyntra Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 4:02 PM EDT - 11 months ago

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 18, 2025, 7:00 AM EDT - 11 months ago

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

Aug 11, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings Call Transcript: Q2 2025

Aug 11, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Quarterly report: Q2 2025

Aug 11, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings release: Q2 2025

Aug 11, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Slides: Q2 2025

Aug 11, 2025, 4:02 PM EDT - 1 year ago

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 4, 2025, 4:02 PM EDT - 1 year ago

FibroGen to Report Second Quarter 2025 Financial Results

Jun 12, 2025, 4:02 PM EDT - 1 year ago

FibroGen Announces 1-for-25 Reverse Stock Split

Jun 9, 2025, 4:02 PM EDT - 1 year ago

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

May 12, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings Call Transcript: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Quarterly report: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings release: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Slides: Q1 2025

May 12, 2025, 4:02 PM EDT - 1 year ago

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:24 AM EDT - 1 year ago

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

May 5, 2025, 4:05 PM EDT - 1 year ago

FibroGen to Report First Quarter 2025 Financial Results

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Kyntra Bio Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Kyntra Bio Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Kyntra Bio Proxy statement: Proxy Filing

Apr 2, 2025, 4:05 PM EDT - 1 year ago

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings Call Transcript: Q4 2024

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Annual report: Q4 2024

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings release: Q4 2024

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Slides: Q4 2024

Mar 17, 2025, 4:05 PM EDT - 1 year ago

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 4:45 PM EST - 1 year ago

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

Feb 20, 2025, 8:30 AM EST - 1 year ago

Kyntra Bio Transcript: Status Update

Feb 20, 2025, 8:30 AM EST - 1 year ago

Kyntra Bio Press release: Status Update

Feb 20, 2025, 8:30 AM EST - 1 year ago

Kyntra Bio Slides: Status Update

Feb 20, 2025, 6:40 AM EST - 1 year ago

FibroGen sells China unit to AstraZeneca in deal worth $160 million

AZN

Feb 20, 2025, 6:30 AM EST - 1 year ago

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

Dec 16, 2024, 8:05 AM EST - 1 year ago

FibroGen Appoints David DeLucia as Chief Financial Officer

Nov 12, 2024, 5:00 PM EST - 1 year ago

Kyntra Bio Earnings Call Transcript: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Kyntra Bio Quarterly report: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Kyntra Bio Earnings release: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Kyntra Bio Slides: Q3 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

FibroGen Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

FibroGen to Report Third Quarter 2024 Financial Results

Sep 10, 2024, 3:00 PM EDT - 2 years ago

Kyntra Bio Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Slides: Q2 2024

Jul 30, 2024, 4:07 PM EDT - 2 years ago

FibroGen to Report Second Quarter 2024 Financial Results

Jun 28, 2024, 8:00 AM EDT - 2 years ago

Kyntra Bio Registration statement: Registration Filing

Jun 10, 2024, 10:00 AM EDT - 2 years ago

Kyntra Bio Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 4:05 PM EDT - 2 years ago

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

Jun 3, 2024, 4:02 PM EDT - 2 years ago

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

May 23, 2024, 5:05 PM EDT - 2 years ago

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology

May 20, 2024, 1:30 PM EDT - 2 years ago

Kyntra Bio Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 7, 2024, 7:00 AM EDT - 2 years ago

FibroGen to Participate in Upcoming Investor Conferences

May 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Earnings Call Transcript: Q1 2024

May 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Quarterly report: Q1 2024

May 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Earnings release: Q1 2024

May 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Slides: Q1 2024

May 6, 2024, 4:02 PM EDT - 2 years ago

FibroGen Reports First Quarter 2024 Financial Results

Apr 29, 2024, 7:00 AM EDT - 2 years ago

FibroGen to Report First Quarter 2024 Financial Results

Apr 24, 2024, 4:02 PM EDT - 2 years ago

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Kyntra Bio Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Kyntra Bio Proxy statement: Proxy Filing

Apr 9, 2024, 3:00 PM EDT - 2 years ago

Kyntra Bio Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 9, 2024, 3:00 PM EDT - 2 years ago

Kyntra Bio Slides: 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 5:46 PM EDT - 2 years ago

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

Mar 26, 2024, 7:00 AM EDT - 2 years ago

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

Mar 11, 2024, 7:00 AM EDT - 2 years ago

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Feb 26, 2024, 5:00 PM EST - 2 years ago

Kyntra Bio Earnings Call Transcript: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Kyntra Bio Annual report: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Kyntra Bio Earnings release: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Kyntra Bio Slides: Q4 2023

Feb 26, 2024, 4:18 PM EST - 2 years ago

FibroGen regains rights to anemia drug from AstraZeneca

AZN

Feb 26, 2024, 4:06 PM EST - 2 years ago

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 26, 2024, 4:05 PM EST - 2 years ago

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

Feb 20, 2024, 7:00 AM EST - 2 years ago

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

Feb 13, 2024, 10:30 AM EST - 2 years ago

Kyntra Bio Transcript: Study Update

Feb 5, 2024, 7:00 AM EST - 2 years ago

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

Jan 25, 2024, 7:00 AM EST - 2 years ago

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

Jan 10, 2024, 3:00 PM EST - 2 years ago

Kyntra Bio Slides: Corporate Presentation

Dec 9, 2023, 5:02 PM EST - 2 years ago

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

Nov 6, 2023, 5:00 PM EST - 2 years ago

Kyntra Bio Earnings Call Transcript: Q3 2023

Nov 6, 2023, 5:00 PM EST - 2 years ago

Kyntra Bio Quarterly report: Q3 2023

Nov 6, 2023, 5:00 PM EST - 2 years ago

Kyntra Bio Earnings release: Q3 2023

Nov 6, 2023, 5:00 PM EST - 2 years ago

Kyntra Bio Slides: Q3 2023

Nov 6, 2023, 4:01 PM EST - 2 years ago

FibroGen Reports Third Quarter 2023 Financial Results

Oct 23, 2023, 7:00 AM EDT - 2 years ago

FibroGen to Report Third Quarter 2023 Financial Results

ARKADIY_PAROVOZOV Jul. 15 at 6:56 AM

$KYNB New notes in Biology (MDPI) related to biological research (possibly HIF pathway). Supportive scientific context for Roxadustat mechanism. https://www.mdpi.com/2079-7737/15/14/1118/notes

0 · Reply

ARKADIY_PAROVOZOV Jul. 15 at 6:55 AM

$KYNB New article in Cell Proliferation discusses cell proliferation mechanisms (possibly related to HIF). Supportive preclinical data. https://onlinelibrary.wiley.com/doi/10.1111/cpr.70230

0 · Reply

ARKADIY_PAROVOZOV Jul. 15 at 6:55 AM

$KYNB Selleckchem overview of renal anemia in CKD and treatment options including HIF-PHI. Educational resource. https://www.selleckchem.com/moa/Renal-Anemia-in-Chronic-Kidney-Disease-S1007.html

0 · Reply

ARKADIY_PAROVOZOV Jul. 15 at 6:54 AM

$KYNB New PubMed article related to Roxadustat or HIF-PHI. Supportive scientific publication. https://pubmed.ncbi.nlm.nih.gov/42417154/

0 · Reply

ARKADIY_PAROVOZOV Jul. 14 at 7:04 AM

0 · Reply

ARKADIY_PAROVOZOV Jul. 14 at 7:04 AM

$KYNB UCSF clinical trials page for prostate cancer. May include FG-3246 studies. https://clinicaltrials.ucsf.edu/prostate-cancer

0 · Reply

ARKADIY_PAROVOZOV Jul. 14 at 7:03 AM

$KYNB Recent company changes tracked on Topograph. Useful for monitoring Kyntra Bio updates. https://topograph.info/changes

0 · Reply

MaxMiamiFl Jul. 14 at 1:31 AM

$KYNB 2nd half of 2026..could be starting 2027.😡😡

0 · Reply

sarah92 Jul. 12 at 6:29 PM

$KYNB Market cap is around $30M, so successful clinical progress could create outsized percentage gains..

1 · Reply

ARKADIY_PAROVOZOV Jul. 9 at 4:35 PM

1 · Reply

ARKADIY_PAROVOZOV Jul. 8 at 7:02 AM

$KYNB New article in Frontiers in Pharmacology explores pharmacological properties of Roxadustat / HIF-PHI. Supportive scientific data for the drug's mechanism and potential applications. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1862547/abstract

0 · Reply

ARKADIY_PAROVOZOV Jul. 7 at 4:29 PM

$KYNB Research from University of Seville on Roxadustat (thesis or study). Additional scientific contribution. https://idus.us.es/items/5dbbd3bf-3f97-4d63-b067-df6c4a42ffc4

0 · Reply

ARKADIY_PAROVOZOV Jul. 7 at 4:29 PM

$KYNB New article in Allergy explores the potential of Roxadustat / HIF-PHI in allergic and inflammatory conditions. Expanding possible applications. https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.70427

0 · Reply

SwingTraderPro1 Jul. 7 at 3:01 PM

Futures are softer, but analyst activity is heating up Notable rating moves and price target updates: $META - Upgraded to Buy @ Erste $HOOD -Jefferies raises PT to $137 from $94 $KYNB -Oppenheimer initiates Outperform, PT $35 $SR - Mizuho initiates Outperform, PT $68 $SPCX - Goldman Sachs initiates Buy, PT $205 Market opens can be noisy, but fresh analyst actions often highlight where institutional attention is rotating. If you want to see the high-conviction stocks I’m watching, my full portfolio, and every trade I make… Head to my profile.

0 · Reply

ARKADIY_PAROVOZOV Jul. 7 at 10:47 AM

$KYNB https://www.investing.com/news/analyst-ratings/oppenheimer-initiates-kyntra-bio-stock-coverage-with-outperform-rating-93CH-4777614

1 · Reply

mjtwins16 Jul. 6 at 10:02 PM

$KYNB

0 · Reply

notreload_ai Jul. 6 at 9:45 PM

Oppenheimer starts coverage on $KYNB with Outperform rating and $35 target. With Phase 2 FG-3246 data expected Q4 2026 and cash into 2028, analysts see major upside potential from current levels. https://notreload.xyz/xy/kyntra-bio-scores-first-analyst-coverage-oppenheimer-initiates-outperform/

0 · Reply

mjtwins16 Jul. 6 at 8:40 PM

$KYNB opco initiates coverage outperform target 35

1 · Reply

ARKADIY_PAROVOZOV Jul. 6 at 12:00 PM

$KYNB New preprint on bioRxiv examines biological mechanisms related to the HIF pathway (Roxadustat class). Early-stage research. https://www.biorxiv.org/content/10.64898/2026.06.29.735161v1.full.pdf

0 · Reply

ARKADIY_PAROVOZOV Jul. 6 at 12:00 PM

$KYNB New PubMed Study (July 2026): A head-to-head study confirms that Roxadustat outperforms conventional Erythropoietin (EPO) in stage 5 CKD patients, delivering a significantly higher mean hemoglobin increase (+2.21 g/dL vs. +2.04 g/dL) and superior iron metabolism. Crucially, its short-term safety profile—including thrombosis and hypertension risks—remained completely comparable to EPO, adding strong independent clinical validation to the molecule's core efficacy. https://pubmed.ncbi.nlm.nih.gov/42375043/

0 · Reply

ARKADIY_PAROVOZOV Jul. 3 at 8:27 AM

$KYNB New preprint on bioRxiv examines biological mechanisms related to the HIF pathway (Roxadustat class). Early-stage research. https://www.biorxiv.org/content/10.64898/2026.06.29.735161v1

0 · Reply

ARKADIY_PAROVOZOV Jul. 3 at 8:27 AM

$KYNB Article on Chinese medical platform discusses Roxadustat for anemia management. Additional supporting regional information. https://www.coagulation-factor-ii.com/index.php?g=Wap&m=Article&a=detail&id=376

0 · Reply

Market Cap	29.73M
Revenue (ttm)	6.44M
Net Income (ttm)	183.45M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	2,848.60%
Debt to Equity Ratio	0.00

Volume	6,240
Avg Vol	21,122
Day's Range	N/A - N/A
Shares Out	4.05M
Stochastic %K	12%
Beta	0.96
Analysts	Strong Sell
Price Target	$36.00